Sugi Predict

Sugi Predict / Compounds / SCHEMBL3973961

SCHEMBL3973961

SCHEMBL3973961

Cc1cc(C(=O)O)c(-c2ccccc2)o1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 4/20 0.62
▸ MAPK1 P28482 1/20 0.62
▸ HSD17B10 Q99714 1/20 0.62
▸ FAAH O00519 2/20 0.49
▸ MGLL Q99685 1/20 0.49
▸ PDE4A P27815 1/20 0.47
▸ ALDH1A1 P00352 3/20 0.47
▸ HPGD P15428 2/20 0.47
▸ MAPT P10636 2/20 0.47
▸ MEN1 O00255 1/20 0.47
▸ NPC1 O15118 1/20 0.47
▸ HTT P42858 1/20 0.47
▸ RAB9A P51151 1/20 0.47
▸ KMT2A Q03164 1/20 0.47
▸ SMN1; SMN2 Q16637 1/20 0.47
▸ LDHA P00338 1/20 0.44
▸ PTGS2 P35354 2/20 0.43
▸ PTPRC P08575 1/20 0.42
▸ PTPN9 P43378 1/20 0.42
▸ PTPN11 Q06124 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL891997 0.86 KDM4E (0.56) KDM4EMAPK1HSD17B10FAAHMGLL
SCHEMBL381345 0.81 FAAH (0.55) KDM4EFAAHMGLLALDH1A1HPGD
SCHEMBL11718771 0.80 ALDH1A1 (0.60) KDM4EMAPK1HSD17B10ALDH1A1HPGD
SCHEMBL4499269 0.79 PDE4A (0.72) KDM4EHSD17B10PDE4AALDH1A1HPGD
SCHEMBL381172 0.76 FAAH (0.54) FAAHMGLLALDH1A1HPGD
SCHEMBL3973087 0.75 KDM4E (0.68) KDM4EMAPK1HSD17B10MAPTMEN1
SCHEMBL2460103 0.74 PTGS2 (0.45) KDM4EMAPK1HSD17B10ALDH1A1HPGD
SCHEMBL10903070 0.73 PTGS2 (0.52) KDM4EMAPK1HSD17B10ALDH1A1HPGD
SCHEMBL13158248 0.72 CHRM2 (0.54) KDM4EMAPK1HSD17B10ALDH1A1HPGD
SCHEMBL546834 0.71 MAPT (0.59) KDM4EALDH1A1HPGDMAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11339130-B1 Calpain modulators and therapeutic uses thereof BLADE THERAPEUTICS, INC. (US) 2022-05-24 — — US disclosed
US-10934261-B2 Calpain modulators and therapeutic uses thereof BLADE THERAPEUTICS, INC. (US) 2021-03-02 — — US disclosed
US-10894776-B2 — — 2021-01-19 — — US disclosed
WO-2018064119-A1 CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF BLADE THERAPEUTICS, INC. (US) 2018-04-05 — — WO disclosed
CN-102659774-A Piperidine and piperazine derivatives as P2X3 antagonists HOFFMANN LA ROCHE 2012-09-12 — — CN disclosed
EP-1917262-B1 PIPERIDINE AND PIPERAZINE DERIVATIVES AS P2X3 ANTAGONISTS HOFFMANN LA ROCHE (CH) 2011-12-14 — — EP disclosed
CN-1894231-B As EP4Furan derivatives as receptor antagonists ASTERAND UK LTD 2011-10-05 — — CN disclosed
US-7569602-B2 Furan derivatives as EP4 receptor antagonists ASTERAND UK LIMITED (GB) 2009-08-04 — — US disclosed
US-7569602-B2 Furan derivatives as EP4 receptor antagonists ASTERAND UK LIMITED (GB) 2009-08-04 — — US disclosed
US-7491821-B2 2-(4-fluorophenyl)-4-propyl-oxazole-5-carboxylic acid {2-[4-(6-aminopyridin-2-yl)-piperazin-1-yl]-1-methyl-ethyl}amide; purinergic receptor antagonists, analgesics; urogenital, gastointestinal and respiratory system disorders ROCHE PALO ALTO LLC (US) 2009-02-17 — — US disclosed
US-20070135503-A1 Furan derivatives as ep4 receptor antagonists ASTERAND UK ACQUISITION LIMITED (GB) 2007-06-14 — — US disclosed
US-20070135503-A1 Furan derivatives as ep4 receptor antagonists ASTERAND UK ACQUISITION LIMITED (GB) 2007-06-14 — — US disclosed
US-20070135503-A1 Furan derivatives as ep4 receptor antagonists ASTERAND UK ACQUISITION LIMITED (GB) 2007-06-14 — — US disclosed
WO-2007020194-A1 PIPERIDINE AND PIPERAZINE DERIVATIVES AS P2X3 ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2007-02-22 — — WO disclosed
US-20070037974-A1 Inhibitors of P2X3 ROCHE PALO ALTO LLC 2007-02-15 — — US disclosed
CN-1894231-A As EP4Furan derivatives as receptor antagonists ASTERAND UK LTD (GB) 2007-01-10 — — CN disclosed
EP-1673360-A1 FURAN DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS ASTERAND UK LIMITED (GB) 2006-06-28 — — EP disclosed
US-20050124676-A1 EP4 receptor antagonists ASTERAND UK ACQUISITION LIMITED (GB) 2005-06-09 — — US disclosed
WO-2005037812-A1 FURAN DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS ASTERAND UK LIMITED (GB) 2005-04-28 — — WO disclosed
US-4025537-A Preparation of 3-carboalkoxy or 3-alkanoyl furans KRETCHMER RICHARD ALLAN 1977-05-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10934261-B2 Calpain modulators and therapeutic uses thereof CAPNS1, CAPN9, CAPN1 KDM4E 3495/4885MAPK1 3457/4885HSD17B10 3550/4885
US-20070037974-A1 Inhibitors of P2X3 P2RX3, P2RX4, P2RX5 KDM4E 1047/4885MAPK1 2290/4885HSD17B10 4394/4885
US-20050124676-A1 EP4 receptor antagonists PTGER4, PTGER3, NR4A3 KDM4E 2329/4885MAPK1 1533/4885HSD17B10 2293/4885
US-10894776-B2 — CAPNS1, CAPN9, CAPN2 KDM4E 3117/4885MAPK1 3624/4885HSD17B10 3140/4885
US-11339130-B1 Calpain modulators and therapeutic uses thereof CAPNS1, CAPN9, CAPN1 KDM4E 3495/4885MAPK1 3457/4885HSD17B10 3550/4885
US-20070135503-A1 Furan derivatives as ep4 receptor antagonists PTGER4, PTGER3, NR4A3 KDM4E 2558/4885MAPK1 1979/4885HSD17B10 2499/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.